Minerva Neurosciences | NERV - Trade Creditors


Minerva Neurosciences reported $640K in Trade Creditors for its fiscal quarter ending in December of 2025.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 44.57M 32.32M Jun/2026
Adma Biologics USD 31.72M 11.2M Jun/2026
ALKERMES USD 142.86M 40.5M Jun/2026
Alterity Therapeutics Limited AUD 1.07M 203.72K Dec/2025
AstraZeneca USD 22.89B 388M Jun/2026
BioCryst Pharmaceuticals USD 11.46M 501K Jun/2026
Bristol-Myers Squibb USD 4.16B 76M Jun/2026
Cipla INR 32.3B 1.95B Mar/2026
Clal Biotechnology ILS 21.05M 1.62M Dec/2021
Compugen USD 2.53M 173K Mar/2026
CSL USD 3.17B 290M Dec/2025
Eli Lilly USD 6.11B 1.08B Jun/2026
GlaxoSmithKline GBP 14.34B 7M Jun/2026
Grifols EUR 987.75M 47.87M Dec/2025
Halozyme Therapeutics USD 23.61M 9.51M Jun/2026
Ionis Pharmaceuticals USD 47.7M 21.67M Jun/2026
J&J USD 9.22B 1.24B Jun/2026
Merck USD 3.83B 36M Jun/2026
Minerva Neurosciences USD 640K 305K Dec/2025
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Novartis USD 4.26B 64M Jun/2026
Novavax USD 22.94M 6.84M Jun/2026
Pfizer USD 4.58B 75M Jun/2026
Roche Holding CHF 5.54B 237M Jun/2026
Sanofi EUR 23.6B 888M Jun/2026
Takeda JPY 446.78B 44.56B Jun/2026
Vanda Pharmaceuticals USD 39.09M 33.28M Dec/2024